Castle Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and test volume growth, with record months for core products and improved margins. Full-year guidance was raised, and new clinical data reinforced product value. Reimbursement clarity for AdvanceAD-Tx is expected by Q3, with material revenue anticipated in 2027–2028.
-
The DECIDE study confirms DecisionDx-Melanoma's strong predictive value for sentinel lymph node positivity and recurrence risk, enabling precise risk stratification and safe de-escalation of care for low-risk melanoma patients. The test outperforms competing assays and is widely adopted in clinical practice, supporting its case for guideline inclusion.
Fiscal Year 2025
-
Delivered strong 2025 results with $344.2M revenue and robust test volume growth, especially for TissueCypher and DecisionDx-Melanoma. 2026 guidance projects continued core growth, with new product launches and pipeline investments supporting long-term expansion.
-
Q3 2025 saw 36% revenue and volume growth, strong cash reserves, and a 77% gross margin. A new non-invasive test for atopic dermatitis was launched, showing high clinical utility and strong clinician interest. Major market opportunities exist in dermatology and gastroenterology.
-
Q3 saw 36% pro forma revenue and volume growth, with strong cash flow and raised guidance. DecisionDx-Melanoma and TissueCypher tests are driving adoption and clinical impact, while new launches and pipeline innovations target large markets. FDA submissions and payer engagement are expected to expand coverage and revenue in coming years.
-
Q3 2025 saw strong revenue growth, record test volumes, and the launch of AdvanceAD-Tx for atopic dermatitis. Guidance for 2025 revenue was raised, with continued momentum in core dermatology and GI franchises, though margins declined year-over-year.
-
Diagnostic test portfolio continues to expand, with strong growth in both dermatology and GI segments. Recent acquisitions and collaborations enhance the pipeline, while new data supports reimbursement efforts. High single-digit growth is expected for melanoma, and GI test volumes remain robust.
-
Q2 saw strong volume and revenue growth, with robust cash flow and a five-year CAGR of 52%. GI and dermatology franchises are both expanding, with new pipeline tests and strategic acquisitions supporting future growth. Medicare reimbursement for SCC is under review, while melanoma and atopic dermatitis tests show promising clinical and commercial prospects.
-
Q2 2025 saw $86.2M in revenue, strong test volume growth, and robust cash reserves. Guidance for 2025 revenue was raised to $310–$320M, with high single-digit volume growth expected for DecisionDx-Melanoma. Key risks include reimbursement changes and payer resistance.
-
Innovative diagnostic tests drive improved patient outcomes and operational growth, with strong clinical evidence supporting reduced invasive procedures and better risk stratification. Financial performance remains robust, with a focus on commercialization, R&D, and strategic expansion.
-
Revenue grew 21% to $88M in Q1 2025, led by 117% growth in TissueCypher and steady DecisionDx-Melanoma volumes. Raised 2025 revenue guidance to $287–$297M, with strong cash reserves and a new GI-focused acquisition, while discontinuing IDgenetix.
-
The discussion highlighted improved CMS reimbursement clarity, strong product adoption, and a balanced growth strategy across commercial, pipeline, and acquisitions. Key products like TissueCypher and DecisionDx-Melanoma are driving growth, with ongoing evidence supporting broader coverage and cost savings.
-
Revenue has grown tenfold since 2018, with future growth focused on TissueCypher and melanoma tests. SCC is being de-emphasized due to reimbursement loss, while IDgenetix faces market and payer challenges. Gross margins will decline but cash flow remains positive, and M&A will be considered selectively.
Fiscal Year 2024
-
2024 saw 51% revenue growth to $332.1M, positive net income, and strong test volume increases across core products. 2025 guidance reflects the loss of Medicare coverage for DecisionDx-SCC, with revenue expected at $280–$295M and continued positive adjusted EBITDA.
-
The company highlighted robust growth in its dermatology and gastroenterology diagnostic test portfolio, supported by strong clinical evidence and expanding publications. Financially, it maintains high margins, disciplined expenses, and expects to remain EBITDA positive in 2025.
-
The company reported strong Q3 results and raised full-year guidance, driven by rapid adoption of its TissueCypher test and expansion of its sales force. New clinical data support the value of its SCC test, while future launches in inflammatory skin disease are planned, with reimbursement as a key focus.
-
The conference highlighted robust growth, strong financials, and expanding clinical evidence for three key diagnostic products. New studies support improved patient outcomes and cost savings, while ongoing adoption and payer engagement position the business for continued success.
-
Q3 2024 saw 39% revenue growth and positive net income, driven by strong test volume across all segments. Full-year revenue guidance was raised to $320–330 million, with continued reimbursement and market expansion expected.
-
Strong Q2 growth was driven by robust test adoption in dermatology and GI, with $87 million in revenue and $24 million in operating cash flow. Market penetration for key tests is expected to double long-term, and the pipeline remains on track for a late 2025 launch.
-
Focused on high-need diagnostics, the company is expanding its sales force and product adoption, especially in dermatology and GI cancer. Strong clinical evidence and financial growth support a positive outlook, with plans to double melanoma test penetration and further optimize operations.
-
Q2 2024 saw 74% revenue growth to $87M, with strong gains across all test franchises and improved margins. Full-year guidance was raised to $275–$300M, though uncertainty remains around CMS coverage for DecisionDx-SCC. Cash position remains robust at $259.7M.